亿帆医药：全资子公司收到易黄汤颗粒境内生产药品注册受理通知书

Core Viewpoint - Yifan Pharmaceutical (002019) announced that its wholly-owned subsidiary, Suzhou Yifan Pharmaceutical Co., Ltd., received the acceptance notice for the domestic production drug registration application for Yihuang Decoction Granules from the National Medical Products Administration on January 6, 2026. This product is the first classic formula variety registered by the company, aimed at kidney strengthening and dampness clearing [1]. Company Summary - Yifan Pharmaceutical's subsidiary has successfully progressed in the drug registration process, indicating a positive step towards bringing Yihuang Decoction Granules to market [1]. - The product is positioned to address specific health needs, focusing on kidney health and the elimination of dampness, which may enhance the company's product portfolio [1].